Genentech’s fenebrutinib challenges the PPMS treatment ceiling but does not yet reset it
Genentech has reported late-breaking Phase III data from the FENtrepid trial showing that its investigational Bruton’s tyrosine kinase inhibitor fenebrutinib achieved non-inferiority to ocrelizumab in reducing disability progression in patients with primary progressive multiple sclerosis. The results were presented at the ACTRIMS Forum 2026 and position fenebrutinib as the first oral, brain-penetrant therapy to directly […]